Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22301691 | 0.89 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL24316281 | 0.87 | CHRM2 (0.35) | L3MBTL1 | |
| SCHEMBL20314971 | 0.86 | PARP1 (0.31) | L3MBTL1PARP1 | |
| SCHEMBL24317699 | 0.85 | — | — | |
| SCHEMBL14788176 | 0.84 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL14788117 | 0.84 | L3MBTL1 (0.34) | L3MBTL1 | |
| SCHEMBL21725587 | 0.83 | L3MBTL1 (0.31) | L3MBTL1 | |
| SCHEMBL2603338 | 0.81 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL2603339 | 0.81 | SLC18A3 (0.32) | L3MBTL1 | |
| SCHEMBL17658848 | 0.81 | DPP7 (0.31) | L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | C 4 Therapeutics, Inc. (US) | 2024-01-18 | — | — | US | disclosed |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2023-06-20 | — | — | US | disclosed |
| WO-2022081925-A1 | TRICYCLIC LIGANDS FOR DEGRADATION OF IKZF2 OR IKZF4 | C4 THERAPEUTICS, INC. (US) | 2022-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018118-A1 | TRICYCLIC COMPOUNDS TO DEGRADE NEOSUBSTRATES FOR MEDICAL THERAPY | NFATC1, CTSS, MMP12 | L3MBTL1 3664/4885PARP1 328/4885 |
| US-11679108-B2 | Aromatic heterocyclic compound, and pharmaceutical composition and use thereof | ENPP2, ADRM1, TPX2 | L3MBTL1 2222/4885PARP1 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.